Note: ER 11/30 Tues
Roth Capital analyst Jonathan Aschoff initiated coverage of BFRI stock with a buy rating and $20 price target. The analyst believes the stock is poised for growth thanks to its U.S. sales plans.
Biofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red light for use in photodynamic therapy. The company was founded in 1997 and is based in Woburn, Massachusetts.
Roth Capital analyst Jonathan Aschoff initiated coverage of BFRI stock with a buy rating and $20 price target. The analyst believes the stock is poised for growth thanks to its U.S. sales plans.
Biofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red light for use in photodynamic therapy. The company was founded in 1997 and is based in Woburn, Massachusetts.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.